Ninety One UK Ltd Purchases 480,496 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ninety One UK Ltd grew its stake in Edwards Lifesciences Co. (NYSE:EW) by 2,740.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 498,029 shares of the medical research company’s stock after buying an additional 480,496 shares during the period. Ninety One UK Ltd’s holdings in Edwards Lifesciences were worth $37,975,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. increased its position in Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after buying an additional 325,808 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Edwards Lifesciences by 0.3% during the second quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock worth $1,934,919,000 after purchasing an additional 66,763 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 9.2% during the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares in the last quarter. Moneta Group Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares in the last quarter. Finally, Brown Advisory Inc. grew its position in shares of Edwards Lifesciences by 5.7% during the third quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after purchasing an additional 818,849 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Truist Financial increased their target price on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Mizuho increased their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Evercore ISI increased their price target on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, Citigroup increased their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Insider Buying and Selling

In related news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. In the last three months, insiders sold 194,004 shares of company stock valued at $17,166,254. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $86.45 on Friday. The firm has a market capitalization of $52.04 billion, a price-to-earnings ratio of 37.59, a PEG ratio of 4.32 and a beta of 1.05. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The business has a 50 day simple moving average of $90.14 and a 200-day simple moving average of $78.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.